Inotropes and vasopressors: More than haemodynamics!

British Journal of Pharmacology

Volumn 165, Issue 7, 2012, Pages 2009-2011

  Bracht, Hendrik ^a   Calzia, Enrico ^a   Georgieff, Michael ^a   Singer, Joel ^b   Radermacher, Peter ^a   Russell, James A ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b ST PAUL S HOSPITAL   (Canada)

Author keywords

carbohydrate metabolism; catecholamine; hypotension; inflammatory response; intestinal motility; PDE inhibitor; vasopressin

Indexed keywords

ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ADRENALIN; DOPAMINE; GLIBENCLAMIDE; HYPERTENSIVE AGENT; HYPERTENSIVE FACTOR; INOTROPIC AGENT; LEVOSIMENDAN; METHYLENE BLUE; N(G) METHYLARGININE; NORADRENALIN; PHENYLEPHRINE; PHOSPHODIESTERASE INHIBITOR; VASOPRESSIN DERIVATIVE;

BLOOD VOLUME; CARDIOGENIC SHOCK; CLINICAL PHARMACOLOGY; DISEASE ASSOCIATION; DRUG CHOICE; DRUG MECHANISM; DRUG RESPONSE; ENERGY METABOLISM; FLUID THERAPY; GASTROINTESTINAL MOTILITY; HEMODYNAMICS; HUMAN; HYPOTENSION; IATROGENIC DISEASE; IMMUNE SYSTEM; IMMUNOMODULATION; INTENSIVE CARE; KIDNEY FAILURE; MORTALITY; OXIDATIVE STRESS; PERFUSION PRESSURE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY; REVIEW; SEPTIC SHOCK; SHOCK; SURVIVAL RATE; VASOCONSTRICTION;

ANIMALS; CARDIOTONIC AGENTS; CRITICAL CARE; CRITICAL ILLNESS; HUMANS; VASOCONSTRICTOR AGENTS;

EID: 84858163805     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2011.01776.x     Document Type: Review

References (33)

1. G-methyl-L-arginine hydrochloride (546C88) by intravenous infusion for up to 72 hours can promote resolution of shock in patients with severe sepsis: results of a randomized, double-blind, placebo-controlled multicenter study (study no. 144-02). Crit Care Med 32: 1-12. (Pubitemid 38125557)
2. Bangash MN, Kong ML, Pearse R, (2012). Use of inotropes and vasopressor agents in critically ill patients. Br J Pharmacol 165: 2015-2033.
3. Bearn AG, Billing B, Sherlock S, (1951). The effect of adrenaline and noradrenaline on hepatic blood flow and splanchnic carbohydrate metabolism in man. J Physiol 115: 430-441.
4. Brame AL, Singer M, (2010). Stressing the obvious? An allostatic look at critical illness. Crit Care Med 38 (10 Suppl.): S600-S607.
5. Carpati CM, Astiz ME, Rackow EC, (1997). Optimizing gastric mucosal perfusion: all catecholamines may not be created equal. Crit Care Med 25: 1624-1625. (Pubitemid 27435490)
6. Cori CF, Cori G, (1928). The mechanism of epinephrine action. I: the influence of epinephrine on carbohydrate metabolism of fasting rats, with a note on new formation of carbohydrates. J Biol Chem 79: 309-319.
7. De Backer D, Creteur J, Silva E, Vicent JL, (2003). Effects of dopamine, norepinephrine, and epinephrine on the splanchnic circulation in septic shock: which is the best? Crit Care Med 31: 1659-1667. (Pubitemid 36714218)
8. De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, et al,. (2010). Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 362: 779-789.
9. Dünser MW, Ruokonen E, Pettilä V, Ulmer H, Torgersen C, Schmittinger CA, et al,. (2009a). Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care 13: R181.
10. Dünser MW, Takala J, Ulmer H, Mayr VD, Luckner G, Jochberger S, et al,. (2009b). Arterial blood pressure during early sepsis and outcome. Intensive Care Med 35: 1225-1233.
11. Flierl MA, Rittirsch D, Huber-Lang M, Sarma JV, Ward PA, (2008). Catecholamines-crafty weapons in the inflammatory arsenal of immune/inflammatory cells or opening Pandora's box? Mol Med 14: 195-204. (Pubitemid 351481850)
12. Gordon AC, Russell JA, Walley KR, Singer J, Ayers D, Storms MM, et al,. (2010). The effects of vasopressin on acute kidney injury in septic shock. Intensive Care Med 36: 83-91.
13. Heringlake M, Wernerus M, Grünefeld J, Klaus S, Heinze H, Bechtel M, et al,. (2007). The metabolic and renal effects of adrenaline and milrinone in patients with myocardial dysfunction after coronary artery bypass grafting. Crit Care 11: R51.
14. Juffermans NP, Vervloet MG, Daemen-Gubbels CR, Binnekade JM, de Jong M, Groeneveld AB, (2010). A dose-finding study of methylene blue to inhibit nitric oxide actions in the hemodynamics of human septic shock. Nitric Oxide 22: 275-280.
15. Kirov MY, Evgenov OV, Evgenov NV, Egorina EM, Sovershaev MA, Sveinbjrnsson B, et al,. (2001). Infusion of methylene blue in human septic shock: a pilot, randomized, controlled study. Crit Care Med 29: 1860-1867. (Pubitemid 32980392)
16. Koo DJ, Chaudry IH, Wang P, (2000). Mechanism of hepatocellular dysfunction during sepsis: the role of gut-derived norepinephrine. Int J Mol Med 5: 457-465.
17. Loick HM, Möllhoff T, Berendes E, Hammel D, Van Aken H, (1997). Influence of enoximone on systemic and splanchnic oxygen utilization and endotoxin release following cardiopulmonary bypass. Intensive Care Med 23: 267-675.
18. Lõpez A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, et al,. (2004). Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med 32: 21-30. (Pubitemid 38125559)
19. Lünemann JD, Buttgereit F, Tripmacher R, Baerwald CG, Burmester GR, Krause A, (2001). Norepinephrine inhibits energy metabolism of human peripheral blood mononuclear cells via adrenergic receptors. Biosci Rep 21: 627-635. (Pubitemid 34816192)
20. McDougal MD, West GB, (1954). The inhibition of the peristaltic reflex by sympathomimetic amines. Br J Pharmacol Chemother 9: 131-137.
21. Pichot C, Géloën A, Ghignone M, Quintin L, (2010). Alpha-2 agonists to reduce vasopressor requirements in septic shock? Med Hypotheses 75: 652-656.
22. Van Der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF, (1996). Epinephrine inhibits tumor necrosis factor-α and potentiates interleukin 10 production during human endotoxemia. J Clin Invest 97: 713-719. (Pubitemid 26057090)
23. Rivers E, Nguyen B, Havstad S, Ressler J, Knoblich B, Petersen E, et al,. (2001). Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 345: 1368-1377.
24. Rump AF, Klaus W, (1994). Evidence for norepinephrine cardiotoxicity mediated by superoxide anion radicals in isolated rabbit hearts. Naunyn Schmiedebergs Arch Pharmacol 349: 295-300. (Pubitemid 24095711)
25. Russell JA, Walley KR, (2010). Vasopressin and its immune effects in septic shock. J Innate Immun 2: 446-460.
26. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, et al,. (2008). Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 358: 877-887. (Pubitemid 351397087)
27. Silverman HJ, Penaranda R, Orens JB, Lee NH, (1993). Impaired beta-adrenergic receptor stimulation of cyclic adenosine monophosphate in human septic shock: association with myocardial hyporesponsiveness to catecholamines. Crit Care Med 21: 31-39. (Pubitemid 23028473)
28. Simon F, Giudici R, Scheuerle A, Gröger M, Asfar P, Vogt JA, et al,. (2009). Comparison of cardiac, hepatic, and renal effects of arginine vasopressin and noradrenaline during porcine fecal peritonitis: a randomized controlled trial. Crit Care 13: R113.
29. Singer M, (2007). Catecholamine treatment for shock-equally good or bad? Lancet 370: 636-637. (Pubitemid 47285300)
30. Singer M, Matthay MA, (2011). Clinical review: thinking outside the box-an iconoclastic view of current practice. Crit Care 15: 225.
31. Singer M, Coluzzi F, O'Brien A, Clapp LH, (2005). Reversal of life-threatening, drug-related potassium-channel syndrome by glibenclamide. Lancet 365: 1873-1875. (Pubitemid 40744965)
32. Wagner K, Calzia E, Georgieff M, Radermacher P, Wagner F, (2011). A mouse is not a man-should we abandon murine models in critical care research? Crit Care Med 39: 2371-2373.
33. Warrillow S, Moritoki E, Bellomo R, (2006). Randomized, double-blind, placebo-controlled crossover pilot study of potassium channel blockers in patients with septic shock. Crit Care Med 34: 980-985.